Last reviewed · How we verify
TOP1288
At a glance
| Generic name | TOP1288 |
|---|---|
| Also known as | TOP1288 Placebo |
| Sponsor | Topivert Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects (PHASE1)
- Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (PHASE2)
- Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOP1288 CI brief — competitive landscape report
- TOP1288 updates RSS · CI watch RSS
- Topivert Pharma Ltd portfolio CI